# Racetams Rating: Early — Mostly animal or cell studies; few or uncontrolled human data Type: Compound Updated: 2026-10-14 Canonical: https://heretic.bio/articles/racetams.html > Racetams are synthetic nootropics built on a pyrrolidone core, modulating AMPA glutamate and cholinergic signaling. The honest verdict: piracetam has real, narrow clinical wins (cortical myoclonus, dyslexia adjunct, post-stroke and post-ECT cognitive recovery), but the 2024 AAN meta-analysis of 18 randomized trials found no significant memory benefit versus placebo. The newer racetams (aniracetam through noopept) rest mostly on older European and Russian trials never replicated in the West. None are FDA-approved for cognition; phenylpiracetam is WADA-banned. ## Overview The **racetams** are a class of synthetic nootropic compounds sharing a **pyrrolidone nucleus** (2-oxo-1-pyrrolidine-acetamide) at their chemical core. The first racetam — **Piracetam** — was synthesized by **Dr. Corneliu Giurgea** at UCB Pharma (Belgium) in 1964. Originally screened as a calming agent for motion sickness, Giurgea observed it instead **enhanced cognition without sedation** , leading him to coin the term "nootropic" in 1972. All racetams modulate glutamatergic transmission (AMPA/NMDA receptors) and cholinergic pathways, and are typically co-administered with a choline donor (Alpha-GPC or CDP-choline) to prevent the "racetam headache" and support substrate availability. They are not classical psychostimulants — they do not produce wakefulness, euphoria, or sympathomimetic effects. > ⚠️ **Legal note (US):** Piracetam is a Schedule 5-exempt drug in some states (e.g. West Virginia) but is not FDA-approved for any indication; it cannot be sold as a dietary supplement and is marketed "for research use only." Piracetam is approved in Europe (Nootropil) for myoclonus and as adjunctive cortical myoclonus therapy. Most other racetams (aniracetam, oxiracetam, pramiracetam, phenylpiracetam, coluracetam, noopept) are not FDA-approved for human use and occupy a similar gray-market status. Phenylpiracetam is a **WADA-banned substance** (S6 — stimulants). ## The 7 Most-Used Racetams (with Evidence Updates 2024–2026) ### 1\. Piracetam — The Original Attribute | Detail ---|--- **Developed** | 1964, UCB Pharma (Belgium); Giurgea **Mechanism** | Positive allosteric modulator of AMPA receptors; indirect NMDA modulation; increases cerebral membrane fluidity; may improve mitochondrial function **Best-evidence uses** | Cortical myoclonus (orphan indication, approved), dyslexia adjunct, post-stroke aphasia recovery, post-electroconvulsive therapy (ECT) cognitive recovery **Cognitive / dementia evidence** | Largely null — see "Modern Meta-Analyses" below **Dose (clinical)** | — **Onset** | Subtle; days–weeks for full effect #### Modern Meta-Analyses (2024 update) The most rigorous cumulative evidence as of 2024–2025 is mixed-to-null for the _general_ cognitive claims that fueled the original 2000s nootropics movement: * **Fioravanti 2012** (Cochrane-like systematic review): "the evidence is weak for piracetam's efficacy in dementia patients." Cited PMID [12087142](https://pubmed.ncbi.nlm.nih.gov/12087142/) / Cochrane 2004. * **2024 AAN Meta-Analysis** (American Academy of Neurology Annual Meeting 2024, abstract AAN2024-003067): 18 RCTs of piracetam on memory function (n = 886), pooled SMD = **0.75 [95% CI −0.19 to 1.69], p = 0.12** , I² = 96% (high heterogeneity). **No statistically significant memory benefit versus placebo.** This is the most current pooled estimate. * **Lopez-Sanchez et al. 2024** (PMID [38878641](https://pubmed.ncbi.nlm.nih.gov/38878641/), _J Alzheimers Dis_): experimental study confirming piracetam's modulation of synaptic plasticity markers but not demonstrating clinical cognitive benefit in cognitively intact adults. * **Waegemans 2002** (PMID [11926227](https://pubmed.ncbi.nlm.nih.gov/11926227/), _Dement Geriatr Cogn Disord_ — historical anchor): mild benefit on clinical global impression in mild-to-moderate dementia; the most-cited "positive" trial, but later meta-analyses pool this with multiple null/negative trials and the net effect is null. **Bottom line:** Piracetam has **narrow clinically demonstrated efficacy** (myoclonus, dyslexia, post-stroke/ECT recovery) but **fails pooled cognition/dementia meta-analyses**. The 2000s "smart drug" framing significantly overstated the evidence base. ### 2\. Aniracetam — The Creative / Anxiolytic One Attribute | Detail ---|--- **Developed** | 1970s, Hoffmann-La Roche **Mechanism** | AMPA potentiation (kainate/AMPA-selective); 5-HT2A modulation; dopaminergic facilitation **Best for** | Anxiety + cognition combination ("relaxed focus"), creativity, holistic thinking **Dose** | — **Half-life** | ~1–2.5 h — short; needs 2–3× daily dosing **Recent evidence:** \- **[PMC6493642](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493642/) (2019, _Front Pharmacol_)**: Clinical efficacy of aniracetam monotherapy or combination therapy in patients with mild cognitive impairment — modest signal on MMSE, ADL. \- **eNeuro 2025 (12:3 ENEURO.0578-24.2025)** : aniracetam ameliorates ADHD-like behavior in adolescent mice, with cholinergic and glutamatergic effects. \- **Russian-origin / clinical** : aniracetam is registered and used in Russia and China for vascular cognitive impairment and post-stroke recovery; little high-quality Western RCT replication. ### 3\. Oxiracetam — The Logical One Attribute | Detail ---|--- **Developed** | 1977, ISF (Italy) **Mechanism** | AMPA/kainate modulation; modest cholinergic; water-soluble **Best for** | Technical / logical tasks, memory consolidation **Dose** | — **Character** | Mildly stimulating without sympathomimetic side effects Evidence base is dominated by **older European trials (1980s–90s)** showing modest benefit in vascular dementia and post-stroke recovery; no major 2024–2026 RCTs. Oxiracetam is registered in Italy (Neuromet) for cognitive deficits of organic origin. ### 4\. Pramiracetam — The Intense One Attribute | Detail ---|--- **Developed** | Warner-Lambert / Parke-Davis (1979) **Mechanism** | Increases high-affinity choline uptake (HACU); AMPA/NMDA modulation **Best for** | Intense focus, prolonged study sessions, memory consolidation **Dose** | — **Character** | Lipophilic; one of the most potent racetams **Evidence:** \- **Pramiracetam vs. piracetam head-to-head (Marini et al. 1990,_Eur J Clin Pharmacol_)**: pramiracetam superior to piracetam in multi-infarct dementia at lower mg dose (1,200 mg vs. 4,800 mg). \- Recent status: pramiracetam is one of several compounds being **re-evaluated** as adjunct therapy in cognitive decline trials (e.g., as a positive control in Cognition Therapeutics' CT1812 trial program — see 2024 trial disclosures). No large phase 3 trial since the 1990s. ### 5\. Phenylpiracetam (Phenotropil / Carphedon) — The Powerful One Attribute | Detail ---|--- **Developed** | 1983, Russian Academy of Sciences (Institute of Biomedical Problems) **Mechanism** | Piracetam analog with phenyl group; modulates NMDA, dopamine D2/D3, nicotinic acetylcholine receptors; increases BDNF **Approved dose (Russia)** | — **Best for** | Physical + cognitive stamina; fatigue, cold, hypoxia **WADA status** | **Banned** in sport since 2019 (S6 — stimulants) **Unique history** | Developed for Soviet/Russian cosmonauts and military personnel for performance under stress (cold, hypoxia, fatigue) > **Compliance caution:** Phenylpiracetam is WADA-banned. Athletes subject to testing should not use. It is also anecdotally one of the most habit-prone racetams due to its dopaminergic action and the rapid loss of effect with continuous use. ### 6\. Coluracetam — The Mood / Choline-Uptake One Attribute | Detail ---|--- **Developed** | Mitsubishi Tanabe Pharma (originally MKC-231) **Mechanism** | High-affinity choline uptake (HACU) enhancer; preserves HACU in damaged neurons **Best for** | Memory, mood, depression, anxiety **Dose** | — **Unique** | Originally developed for Alzheimer's disease; Mitsubishi halted Phase 2 in the 2000s after a strategic re-prioritization, not due to safety or efficacy signals **Evidence:** \- **MKC-231 animal work** : positive effects on choline uptake and memory in cholinergic-lesion models. \- **No new published Phase 2/3 RCTs of coluracetam since 2010** — it is now sold as a research chemical only. Anecdotal reports of anxiolytic and mood-lifting effects in users who tolerate racetams poorly; no rigorous human data to support these claims. ### 7\. Noopept (N-Phenylacetyl-L-prolylglycine ethyl ester / GVS-111) > **Note:** Noopept is technically not a racetam (cyclopropyl-glycine proline derivative) but is conventionally grouped with racetams due to mechanism, effect profile, and Russian origin. Attribute | Detail ---|--- **Developed** | 1990s, Zakusov Institute of Pharmacology (Russia) **Mechanism** | Increases BDNF and NGF expression; modulates AMPA/NMDA; anti-apoptotic; reduces tau hyperphosphorylation **Best for** | Memory, learning, neuroprotection, post-stroke recovery **Dose** | — **Character** | ~1000× more potent than piracetam by weight **Approved (Russia/CIS)** | Noopept (brand Noopept / Ноопепт): cognitive impairment of vascular and post-traumatic origin ## Essential Co-Factor: Choline Choline Source | Potency | Notes ---|---|--- **Alpha-GPC** | High | Crosses BBB efficiently; 300–600 mg; ~40% choline by mass **CDP-Choline (Citicoline)** | High | Supports membrane phospholipid synthesis; 250–500 mg **Centrophenoxine** | Very High | More potent (DMAE + parachlorophenoxyacetate); 250–500 mg > **Practical note:** Most "racetam headaches" reported by users are choline-depletion headaches; they typically resolve within 30 minutes of a choline donor dose. If headaches persist on full choline support, that racetam may not be a good individual fit (anecdotal, but consistent across reports). ## Comparison Summary Racetam | Memory | Focus | Energy | Anxiety relief | Creativity | Potency | Human RCT depth ---|---|---|---|---|---|---|--- **Piracetam** | ⭐⭐⭐ | ⭐⭐ | ⭐ | ⭐ | ⭐⭐ | Low | Deep (multiple meta-analyses) **Aniracetam** | ⭐⭐⭐ | ⭐⭐⭐ | ⭐⭐ | ⭐⭐⭐⭐ | ⭐⭐⭐⭐ | Medium | Modest **Oxiracetam** | ⭐⭐⭐⭐ | ⭐⭐⭐ | ⭐⭐⭐ | ⭐ | ⭐⭐ | Medium | Older European **Pramiracetam** | ⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐ | ⭐ | ⭐ | High | Older trials **Phenylpiracetam** | ⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐ | ⭐⭐ | Very High | Mostly Russian **Coluracetam** | ⭐⭐⭐ | ⭐⭐⭐ | ⭐⭐ | ⭐⭐⭐⭐ | ⭐⭐ | Medium | None in last 15y **Noopept** | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐ | ⭐⭐⭐ | ⭐⭐ | ⭐⭐⭐ | Ultra | Mostly Russian ## Evidence at a Glance Indication | Best Evidence | Verdict ---|---|--- **Cortical myoclonus** | Piracetam (FDA orphan, EMA approved) | Effective **Dyslexia (children)** | Piracetam (Di Ieva 1999 PMID [10492051](https://pubmed.ncbi.nlm.nih.gov/10492051/)) | Modest signal; widely used in EU **Post-stroke aphasia / recovery** | Piracetam + Noopept (Russian trials) | Modest signal **ECT cognitive recovery** | Piracetam (small RCTs) | Modest signal **Mild cognitive impairment / dementia (general)** | Piracetam 2024 meta-analysis SMD 0.75 [−0.19, 1.69] | **Null** **Healthy adults / cognition** | Piracetam 2024 meta-analysis | **Null** **Multi-infarct dementia** | Pramiracetam > Piracetam | Modest signal (older trials) **ADHD-like behavior (mouse)** | Aniracetam 2025 eNeuro | Preclinical ## Practical Notes * **For general cognitive enhancement in healthy adults** : the 2024 AAN meta-analysis and Cochrane reviews do not support racetams for cognitive enhancement. Lifestyle factors (sleep, exercise, glycemic control) have far stronger evidence. * **For narrow clinical indications** (myoclonus, post-ECT cognitive fog, dyslexia): piracetam has the best evidence; consult a physician. * **Choline co-administration** : practical necessity for most users; Alpha-GPC or CDP-Choline at the doses above. * **Stacking with caution** : combining 2+ racetams is common in user reports but lacks RCT support; choline demand scales with racetam dose and combination. ## Notes * **Incentive / source bias** : most modern racetam promotion comes from commercial supplement vendors (Mind Lab Pro, Nootropics Expert, Examine.com). Major peer-reviewed RCTs since 2010 are sparse. * **Western regulatory status** : in the US, racetams are typically sold "for research use only" — quality varies substantially; see 01 - Peptides/Peptide Sources and Quality for related supply-chain concerns. * **Russian / CIS literature** : substantial clinical experience exists for aniracetam, noopept, and phenylpiracetam in Russian/CIS medicine that has not been replicated in Western trials. The 12 - Lost Soviet Medical Knowledge section has more on the lineage of this work. * **2024 AAN finding** : the null pooled effect should temper over-confident claims from older or non-systematic reviews. N-of-1 individual benefit cannot be ruled out from a null meta-analysis, but the population case is weak. ## Secondary / Commercial Sources (used with caution) * Nootropics Expert, "Top 7 Racetams" (practitioner guide; commercial, not linked) * Examine.com — [Piracetam Research](https://examine.com/supplements/piracetam/research) and [Noopept Research](https://examine.com/supplements/noopept/research) — best neutral synthesis. * Alzheimer's Drug Discovery Foundation — [Piracetam Cognitive Vitality](https://www.alzdiscovery.org/cognitive-vitality/ratings/piracetam) — independent foundation review. * Medsafe NZ — [Classification Status of Racetams](https://www.medsafe.govt.nz/profs/class/Agendas/agen53Racetams.pdf) — regulatory status in NZ. ## Sources 1. Fioravanti, M. & Flicker, L. (Cochrane 2004 / Fioravanti 2012) — Piracetam for dementia or cognitive impairment. PMID 12087142 . "Evidence is weak." (PubMed 12087142) 2. Lopez-Sanchez et al. 2024 — J Alzheimers Dis . Piracetam modulation of synaptic plasticity markers. PMID 38878641 . (PubMed 38878641) 3. Waegemans, T. et al. (2002) — Dement Geriatr Cogn Disord 13:217–224. Piracetam in mild-to-moderate dementia: RCT → CGS confirms global improvement. PMID 11926227 (cited via secondary literature). (PubMed 11926227) 4. PMC6493642 (2019) — Aniracetam clinical efficacy for cognitive impairment. Front Pharmacol . (PMC6493642) 5. PubMed 10492051 (PubMed 10492051) 6. Malykh, A.G. & Sadaie, M.R. (2010) — Drugs 70(3):287–312. Comprehensive review of piracetam and piracetam-like drugs (mechanisms, clinical uses, safety). PMID 20199067 . (PubMed 20199067) 7. PMC4422191 (2015) — Noopept attenuates Aβ-induced tau hyperphosphorylation and apoptosis (mechanistic AD model). J Biomed Sci . (PMC4422191)